Evotec SE reports Q3 results

2025-11-05 16:29

Evotec SE press release (EVO): Q3 group revenues decrease by (7.1)% to € 535.1 m (9M 2024: € 575.7 m)
Total D&PD revenues decrease by (12.3)% to € 392.1 m (9M 2024: € 447.1 m), due to soft demand in the early drug discovery service market; quotations are growing in number and value, negative change orders are declining
Adjusted Group EBITDA totaled € (16.9) m (9M 2024: € (6.0) m) driven by continued underutilization and a high fixed cost base in the D&PD segment as well as costs related to the ramp-up of the JEB Toulouse facility
- Outlook 2028
- - Group revenues CAGR _2024-2028 targeted to be in a range of 8 - 12%
  - Adjusted EBITDA margin 2028 expected to be above 20%
Guidance for full-year 2025 confirmed
- Group revenues expected in the range of € 760 - 800 m (2024: € 797.0 m)
- R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.9 m)
- Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m)

More on Evotec SE